跳至主要内容
临床试验/NCT05214495
NCT05214495已完成2 期

Efficacy of Topical Oral Omega-3 Hydrogel in Prevention of Radiation-induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Controlled Clinical Trial

Basma Morsy1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2022年2月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
36
试验地点
1
主要终点
Oral Mucositis Severity

研究概览

简要总结

Oral mucositis (OM) is recognized as one of the most frequent debilitating sequela encountered by head and neck cancer (HNC) patients treated by radiotherapy. The objective of the study is to assess primarily the effect of topical oral Omega-3 hydrogel in prevention of radiation-induced oral mucositis and secondarily, to test the effect of topical oral Omega-3 hydrogel on oral microbiome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who are going to receive radiotherapy as a treatment of head and neck cancer either as postoperative (adjuvant) therapy or definitive therapy.
  • Patients whose radiotherapy treatment planned dose is 50 Gy or above
  • Males and females with an age not less than 18 years
  • Patients receiving radiotherapy alone or receiving concomitant cisplatin (or carboplatin) with radiotherapy.

排除标准

  • Patients under Anticoagulants such as warfarin, heparin, or aspirin.
  • Patients suffering from any uncontrolled systemic diseases (such as diabetes, cardiovascular, liver disorder, renal dysfunction)
  • Patients with findings of any physical or mental abnormality which would interfere with or be affected by the study procedure.

研究组 & 干预措施

Topical oral Omega-3 hydrogel group

Experimental

Patients will be given topical oral Omega-3 hydrogel

干预措施: topical oral Omega-3 hydrogel (Drug)

Conventional preventive treatment group

Active Comparator

Patients will be given conventional preventive treatment

干预措施: conventional preventive treatment (Drug)

结局指标

主要结局

Oral Mucositis Severity

时间窗: up to 6 weeks

Radiation induced head and neck toxicity will be scored by a scale based on clinical features from Common Terminology Criteria for Adverse Events (CTCAE) v5.0

次要结局

未报告次要终点

研究者

发起方
Basma Morsy
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Basma Morsy

Principal Investigator

Alexandria University

研究点 (1)

Loading locations...

相似试验